Edgewise Therapeutics, Inc.
EWTX
$13.45
$0.423.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -31.58% | -32.73% | -46.71% | -24.90% | -55.26% |
| Total Depreciation and Amortization | 18.01% | 21.13% | 15.84% | 117.84% | 479.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.26% | 66.67% | 49.73% | -2.33% | 50.48% |
| Change in Net Operating Assets | 3,553.23% | 158.01% | 1,033.63% | -16.47% | -103.66% |
| Cash from Operations | -0.47% | -24.10% | -28.99% | -25.29% | -126.32% |
| Capital Expenditure | -70.19% | -13.79% | 70.88% | 93.20% | 95.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.91% | 8.40% | 794.76% | -601.80% | 137.54% |
| Cash from Investing | -22.46% | 8.30% | 985.65% | -647.10% | 135.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.53% | 118,133.33% | 442.01% | 1,147,866.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 0.00% | -- | -- | -42.35% |
| Cash from Financing | -94.54% | 1,679.62% | 429.00% | 1,147,866.67% | 17,587.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.91% | 14.87% | 180.50% | -312.80% | 160.56% |